journal article·2019-04-23

Biodegradable Biomimic Copper/Manganese Silicate Nanospheres for Chemodynamic/Photodynamic Synergistic Therapy with Simultaneous Glutathione Depletion and Hypoxia Relief

Conghui Liu, Dongdong Wang, Shuyuan Zhang, Yaru Cheng, Fan Yang, Yi Xing, Tailin Xu, Haifeng Dong, Xueji Zhang

ACS Nano· Volume 13· Issue 4
Publisher page

Abstract

The integration of reactive oxygen species (ROS)-involved photodynamic therapy (PDT) and chemodynamic therapy (CDT) holds great promise for enhanced anticancer effects. Herein, we report biodegradable cancer cell membrane-coated mesoporous copper/manganese silicate nanospheres (mCMSNs) with homotypic targeting ability to the cancer cell lines and enhanced ROS generation through singlet oxygen (1O2) production and glutathione (GSH)-activated Fenton reaction, showing excellent CDT/PDT synergistic therapeutic effects. We demonstrate that mCMSNs are able to relieve the tumor hypoxia microenvironment by catalytic decomposition of endogenous H2O2 to O2 and further react with O2 to produce toxic 1O2 with a 635 nm laser irradiation. GSH-triggered mCMSNs biodegradation can simultaneously generate Fenton-like Cu+ and Mn2+ ions and deplete GSH for efficient hydroxyl radical (•OH) production. The specific recognition and homotypic targeting ability to the cancer cells were also revealed. Notably, relieving hypoxia and GSH depletion disrupts the tumor microenvironment (TME) and cellular antioxidant defense system, achieving exceptional cancer-targeting therapeutic effects in vitro and in vivo. The cancer cells growth was significantly inhibited. Moreover, the released Mn2+ can also act as an advanced contrast agent for cancer magnetic resonance imaging (MRI). Thus, together with photosensitizers, Fenton agent provider and MRI contrast effects along with the modulating of the TME allow mCMSNs to realize MRI-monitored enhanced CDT/PDT synergistic therapy. It provides a paradigm to rationally design TME-responsive and ROS-involved therapeutic strategies based on a single polymetallic silicate nanomaterial with enhanced anticancer effects.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Beijing Advanced Innovation Center for Materials Genome Engineering, University of Science and Technology Beijing, Beijing 100083, P.R. China

Beijing Key Laboratory for Bioengineering and Sensing Technology, Research Center for Bioengineering and Sensing Technology, School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, P.R. China

Funding

National Natural Science Foundation of China · Ministry of Education of the People's Republic of China · Ministry of Science and Technology of the People's Republic of China · Beijing Municipal Science and Technology Commission · Beijing Key Lab of Plant Resource Research and Development, Beijing Technology and Business University

References (69)

Show source-provided references
1. 10.1039/C6CS00592F10.1039/C6CS00592F ↗
2. 10.1038/nrd280310.1038/nrd2803 ↗
3. 10.1039/C6CS00616G10.1039/C6CS00616G ↗
4. 10.1021/cr500419810.1021/cr5004198 ↗
5. 10.1039/C6CS00271D10.1039/C6CS00271D ↗
6. 10.1002/adfm.20170037110.1002/adfm.201700371 ↗
7. 10.1002/adfm.20170541610.1002/adfm.201705416 ↗
8. 10.1021/acsnano.7b0423010.1021/acsnano.7b04230 ↗
9. 10.1021/acsnano.7b0862810.1021/acsnano.7b08628 ↗
10. 10.7150/thno.2772110.7150/thno.27721 ↗
11. 10.1021/acsnano.6b0752510.1021/acsnano.6b07525 ↗
12. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
13. 10.1021/acs.nanolett.8b0004010.1021/acs.nanolett.8b00040 ↗
14. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
15. 10.1039/C8NH00307F10.1039/C8NH00307F ↗
16. 10.1016/S0926-3373(01)00281-810.1016/S0926-3373(01)00281-8 ↗
17. 10.1002/anie.20151003110.1002/anie.201510031 ↗
18. 10.1021/acs.nanolett.6b0406010.1021/acs.nanolett.6b04060 ↗
19. 10.1002/adma.20170168310.1002/adma.201701683 ↗
20. 10.1002/anie.20180566410.1002/anie.201805664 ↗
21. 10.1002/anie.20171202710.1002/anie.201712027 ↗
22. 10.1021/acsnano.8b0189310.1021/acsnano.8b01893 ↗
23. 10.1021/acs.nanolett.8b0317810.1021/acs.nanolett.8b03178 ↗
24. 10.1021/acsnano.8b0504210.1021/acsnano.8b05042 ↗
25. 10.1002/advs.20180198610.1002/advs.201801986 ↗
26. 10.1002/anie.20181370210.1002/anie.201813702 ↗
27. 10.1021/jacs.8b0871410.1021/jacs.8b08714 ↗
28. 10.1039/C7CS00471K10.1039/C7CS00471K ↗
29. Szatrowski T. P. · Cancer Res. · 1991 · 51 · 794
30. 10.1021/jacs.7b0555910.1021/jacs.7b05559 ↗
31. 10.1021/jacs.6b0429910.1021/jacs.6b04299 ↗
32. 10.1021/acs.chemrev.5b0014810.1021/acs.chemrev.5b00148 ↗
33. 10.1021/acsnano.8b0763510.1021/acsnano.8b07635 ↗
34. 10.1016/1010-6030(93)80035-810.1016/1010-6030(93)80035-8 ↗
35. 10.1016/0960-1686(90)90443-Q10.1016/0960-1686(90)90443-Q ↗
36. 10.1016/j.biomaterials.2017.06.03510.1016/j.biomaterials.2017.06.035 ↗
37. 10.1002/anie.20160550910.1002/anie.201605509 ↗
38. 10.1039/C7BM00798A10.1039/C7BM00798A ↗
39. Glinsky V. V. · Cancer Res. · 2003 · 63 · 3805
40. 10.1021/acsnano.6b0469510.1021/acsnano.6b04695 ↗
41. 10.1021/nl500618u10.1021/nl500618u ↗
42. 10.1021/acs.nanolett.6b0278610.1021/acs.nanolett.6b02786 ↗
43. 10.1021/acsnano.7b0253310.1021/acsnano.7b02533 ↗
44. 10.1021/acsnano.7b0835510.1021/acsnano.7b08355 ↗
45. 10.1021/cr300358b10.1021/cr300358b ↗
46. Kuppusamy P. · Cancer Res. · 2002 · 62 · 307
47. 10.1021/acs.nanolett.8b0293310.1021/acs.nanolett.8b02933 ↗
48. 10.1021/ja311687310.1021/ja3116873 ↗
49. 10.1021/am506653n10.1021/am506653n ↗
50. 10.1039/b816751f10.1039/b816751f ↗
51. 10.1039/C5RA14294F10.1039/C5RA14294F ↗
52. 10.1021/acsnano.7b0892810.1021/acsnano.7b08928 ↗
53. 10.1002/chem.20090279910.1002/chem.200902799 ↗
54. 10.1002/adfm.20140256010.1002/adfm.201402560 ↗
55. 10.1038/srep1754210.1038/srep17542 ↗
56. 10.1021/cr040204o10.1021/cr040204o ↗
57. 10.1016/j.actbio.2015.11.03610.1016/j.actbio.2015.11.036 ↗
58. 10.1002/smll.20160062410.1002/smll.201600624 ↗
59. 10.1021/acsami.6b1286510.1021/acsami.6b12865 ↗
60. 10.1021/nn300934k10.1021/nn300934k ↗
61. 10.1016/S0076-6879(02)47021-810.1016/S0076-6879(02)47021-8 ↗
62. 10.1080/1040836050052387810.1080/10408360500523878 ↗
63. 10.1016/j.jhazmat.2017.10.02010.1016/j.jhazmat.2017.10.020 ↗
64. 10.1016/j.cej.2016.07.08810.1016/j.cej.2016.07.088 ↗
65. 10.1002/adma.20170675910.1002/adma.201706759 ↗
66. 10.1038/nature0773310.1038/nature07733 ↗
67. 10.1021/acs.nanolett.8b0390510.1021/acs.nanolett.8b03905 ↗
68. 10.1002/adma.20170396910.1002/adma.201703969 ↗
69. 10.1002/adfm.20150105010.1002/adfm.201501050 ↗